IceCure Medical Ltd. (NASDAQ:ICCM – Get Free Report) has been assigned an average rating of “Hold” from the five brokerages that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have issued a buy recommendation on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $62.70.
A number of analysts have recently issued reports on ICCM shares. Weiss Ratings restated a “sell (e+)” rating on shares of IceCure Medical in a report on Tuesday, April 21st. Alliance Global Partners started coverage on shares of IceCure Medical in a report on Monday, May 4th. They set a “buy” rating for the company. Finally, Maxim Group cut their price target on shares of IceCure Medical from $90.00 to $30.00 and set a “buy” rating for the company in a report on Thursday, May 14th.
Read Our Latest Research Report on ICCM
IceCure Medical Price Performance
IceCure Medical (NASDAQ:ICCM – Get Free Report) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.03). The firm had revenue of $0.91 million for the quarter, compared to analyst estimates of $1.34 million. IceCure Medical had a negative return on equity of 211.73% and a negative net margin of 441.60%. As a group, research analysts expect that IceCure Medical will post -3.51 EPS for the current year.
Key IceCure Medical News
Here are the key news stories impacting IceCure Medical this week:
- Positive Sentiment: IceCure Medical said it has regained compliance with Nasdaq’s minimum bid price requirement, removing a near-term listing concern that can often pressure small-cap stocks. IceCure Regains Compliance with Nasdaq Minimum Bid Price Requirement
- Positive Sentiment: Brookline Capital Markets raised near-term and mid-term EPS estimates for IceCure Medical, including higher forecasts for Q2 2026, Q3 2026, FY2026, FY2027, and FY2028, suggesting a slightly better outlook for profitability trends. Icecure Medical Earnings Estimates, EPS & Revenue | NASDAQ:ICCM
- Neutral Sentiment: Short interest fell sharply in mid-June, which can reduce bearish pressure, although there was also a conflicting data entry showing zero shares short, making the signal somewhat unclear.
- Neutral Sentiment: The latest analyst revisions still point to significant losses in the coming years, even though the estimates improved in several periods. This keeps the stock’s longer-term valuation story uncertain.
- Negative Sentiment: IceCure remains unprofitable, and the company previously reported a quarterly EPS loss that missed expectations along with revenue below estimates, which likely continues to weigh on investor sentiment.
Institutional Trading of IceCure Medical
A number of hedge funds and other institutional investors have recently made changes to their positions in ICCM. Virtu Financial LLC acquired a new stake in IceCure Medical in the 4th quarter valued at approximately $39,000. Concurrent Investment Advisors LLC purchased a new stake in IceCure Medical in the fourth quarter valued at approximately $48,000. Finally, Jane Street Group LLC purchased a new stake in IceCure Medical in the fourth quarter valued at approximately $67,000. Institutional investors and hedge funds own 0.62% of the company’s stock.
IceCure Medical Company Profile
IceCure Medical Ltd. (NASDAQ: ICCM) is a clinical-stage medical device company specializing in the development and commercialization of proprietary cryoablation systems for the treatment of tumors and other pathological tissues. The company’s core technology employs a unique liquid-nitrogen-based platform to deliver rapid cooling through fine-gauge cryoprobes, enabling precise and minimally invasive tissue ablation under imaging guidance. IceCure’s lead product, ProSense, is designed to offer a single-probe approach that can be deployed in an outpatient setting, reducing procedure time and patient recovery periods.
Originally founded in Israel, IceCure Medical obtained its first CE mark for the treatment of benign breast tumors and fibroadenomas in 2017.
Read More
- Five stocks we like better than IceCure Medical
- 3 Stocks That Could Benefit as the Robotaxi Race Heats Up
- 3 Waste Stocks Turning AI Investments into Growth
- 3 Overlooked Tech ETFs That Are Quietly Killing It This Year
- 3 ETFs Pairing Market-Beating Returns With High Dividend Yields
Receive News & Ratings for IceCure Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IceCure Medical and related companies with MarketBeat.com's FREE daily email newsletter.
